The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Aspen Pharmacare (APNHY) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Aspen Pharmacare is a member of our Medical group, which includes 915 different companies and currently sits at #9 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Aspen Pharmacare is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for APNHY's full-year earnings has moved 7.6% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, APNHY has returned 44.6% so far this year. In comparison, Medical companies have returned an average of 3.2%. This shows that Aspen Pharmacare is outperforming its peers so far this year.
Another stock in the Medical sector, Corcept Therapeutics (CORT), has outperformed the sector so far this year. The stock's year-to-date return is 232.3%.
Over the past three months, Corcept Therapeutics' consensus EPS estimate for the current year has increased 249.3%. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Aspen Pharmacare belongs to the Medical - Generic Drugs industry, a group that includes 12 individual stocks and currently sits at #51 in the Zacks Industry Rank. Stocks in this group have gained about 7.3% so far this year, so APNHY is performing better this group in terms of year-to-date returns.
Corcept Therapeutics, however, belongs to the Medical - Drugs industry. Currently, this 137-stock industry is ranked #165. The industry has moved -4% so far this year.
Investors with an interest in Medical stocks should continue to track Aspen Pharmacare and Corcept Therapeutics. These stocks will be looking to continue their solid performance.
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power .
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Aspen Pharmacare (APNHY): Free Stock Analysis Report
Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).